Skip to main content
    C

    Cytokinetics Inc (CYTK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $63.92
    +0.49 (+0.77%)

    Market Cap: $8.82B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/39)
    Avg Surprise
    -2.21%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.43
    Range$-1.65 - $-1.10
    16 analysts
    EPS Revisions
    10
    0
    7d
    11
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.59+10.0%
    60d ago$-1.55+7.5%
    30d ago$-1.44+0.8%
    7d ago$-1.430.0%
    Current$-1.43
    Revenue Consensus
    $40M
    Range$28M - $51M
    20 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.28
    Range$-1.72 - $-0.08
    16 analysts
    Revenue Consensus
    $83M
    Range$44M - $156M
    21 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.28---
    Sep 26EST
    		-$-1.43---
    Jun 26
    Reported Aug 6
    		$-1.50$-1.63+7.98%Beat-33.9%
    Mar 26
    Reported May 5
    		$-1.67$-1.65-1.21%Miss-22.8%
    Dec 25
    Reported Feb 24
    		$-1.50$-1.56+3.85%Beat-19.0%
    Sep 25
    Reported Nov 5
    		$-1.54$-1.59+3.14%Beat-13.2%
    Jun 25
    Reported Aug 7
    		$-1.12$-1.34+16.42%Beat+14.5%
    Mar 25
    Reported May 6
    		$-1.36$-1.36+0.00%Beat-2.3%
    Dec 24
    Reported Feb 27
    		$-1.26$-1.17-7.33%Miss+8.7%
    Sep 24
    Reported Nov 6
    		$-1.36$-1.24-9.68%Miss-0.7%
    Jun 24
    Reported Aug 8
    		$-1.31$-0.91-43.96%Miss+2.2%
    Mar 24
    Reported May 8
    		$-1.33$-1.17-13.68%Miss+3.6%
    Dec 23
    Reported Feb 27
    		$-1.38$-0.97-42.27%Miss+4.8%
    Sep 23
    Reported Nov 2
    		$-1.35$-0.76-77.63%Miss-5.5%
    Jun 23
    Reported Aug 3
    		$-1.34$-1.24-8.06%Miss-482.6%
    Mar 23
    Reported May 4
    		$-1.38$-1.18-16.95%Miss-35.3%
    Dec 22
    Reported Mar 1
    		$-1.45$-1.21-19.83%Miss-302.8%
    Sep 22
    Reported Nov 3
    		$-1.28$-1.17-9.40%Miss-34.7%
    Jun 22
    Reported Aug 4
    		$-0.23N/A+77.23%Beat+73.3%
    Mar 22
    Reported May 4
    		$-1.02$-0.94-8.51%Miss-54.5%
    Dec 21
    Reported Feb 24
    		$-0.36N/A+57.14%Beat+41.9%
    Sep 21
    Reported Nov 3
    		$-0.95$-0.77-23.38%Miss-1800.0%
    Jun 21
    Reported Aug 5
    		$-0.86$-0.66-30.30%Miss-26.5%
    Mar 21
    Reported May 6
    		$-0.66$-0.60-10.00%Miss+0.0%
    Dec 20
    Reported Feb 25
    		$-0.62$-0.30-106.67%Miss-19.2%
    Sep 20
    Reported Nov 4
    		$-0.05N/A+85.29%Beat+90.0%
    Jun 20
    Reported Aug 6
    		$-0.68$-0.57-19.30%Miss-21.4%
    Mar 20
    Reported May 6
    		$-0.66$-0.50-32.00%Miss-22.2%
    Dec 19
    Reported Mar 3
    		$-0.52$-0.44-18.18%Miss-8.3%
    Sep 19
    Reported Oct 31
    		$-0.50$-0.49-2.04%Miss-25.0%
    Jun 19
    Reported Aug 8
    		$-0.56$-0.50-12.00%Miss-9.8%
    Mar 19
    Reported May 9
    		$-0.54$-0.47-14.89%Miss+3.6%
    Dec 18
    Reported Feb 21
    		$-0.48$-0.52+7.69%Beat+36.0%
    Sep 18
    Reported Nov 1
    		$-0.40$-0.52+23.08%Beat+33.3%
    Jun 18
    Reported Jul 26
    		$-0.51$-0.51+0.00%Beat+15.0%
    Mar 18
    Reported Apr 26
    		$-0.56$-0.58+3.45%Beat+9.7%
    Dec 17
    Reported Feb 15
    		$-0.75$-0.70-7.14%Miss-568.8%
    Sep 17
    Reported Oct 26
    		$-0.60$-0.62+3.23%Beat-
    Jun 17
    Reported Aug 2
    		$-0.60$-0.60+0.00%Beat-
    Mar 17
    Reported Apr 27
    		$-0.62$-0.61-1.64%Miss-
    Dec 16
    Reported Feb 16
    		$0.16$-0.26+161.54%Beat-

    Key Metrics

    Valuation
    P/E Ratio-10.29EV/EBITDAN/A
    Price/FCF-14.54xFCF Yield-6.88%
    Profitability
    Profit Margin0.00%Operating Margin-626.00%
    ROE-572.00%ROIC-56.36%
    Financial Health
    Debt/Equity-6.61xInterest Coverage-2.82x
    Current Ratio6.66xQuick Ratio6.66x
    Trading Statistics
    Beta0.41Avg Volume2.26M
    52-Week High$88.3152-Week Low$54.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$62.74
    SMA 20$64.54
    SMA 50$70.65
    SMA 200$70.13
    EMA 10$63.36
    EMA 20$64.97
    EMA 50$69.16
    EMA 200$68.61

    MACD

    Line: -2.38Signal: -2.68Hist: 0.30

    ADX

    ADX: 30.9+DI: 17.6-DI: 22.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down80.0
    PSAR$60.10

    Bollinger Bands

    Upper Band$69.01
    Lower Band$60.07
    %B Position1384%(Upper)
    Band Width0.43

    RSI (14-Day)

    Neutral
    41.2

    Momentum Oscillators

    Stoch %K42.8
    Stoch %D37.5
    Williams %R-44.8
    ROC (10d)-2.6%
    Momentum-1.70
    CCI (20d)-7.8
    MFI (14d)50.6

    Volatility Measures

    ATR (14d)$2.25(3.5%)
    StdDev (20d)2.23
    Hist Vol28.0%(Moderate)

    Volume Flow

    VWAP$64.43
    OBV17.5M
    AD Line5.6M
    CMF (20d)-0.201

    Volume Metrics

    Avg Vol (20d)2.3M
    Vol Ratio0.7x
    VWMA (20d)$64.74

    Pivot Points

    R3$67.65
    R2$65.83
    R1$64.63
    Pivot Point$62.81
    S1$61.61
    S2$59.79
    S3$58.59

    Advanced Oscillators

    TSI-33.50
    Ultimate Osc51.9
    KST-124.53

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$28.62M$19.36M$17.75M$1.94M$66.77M$1.58M$17.18M$463,000$0$835,000$1.67M$378,000
    Cost of Revenue$5.59M$2.55M$2.86M$0$2.42M$1.58M$93.63M$0$0$0$84.98M$0
    Gross Profit$23.03M$16.80M$17.75M$1.94M$64.35M$0$17.18M$463,000$0$835,000$1.67M$378,000
    Operating Expenses$202.20M$200.42M$196.12M$168.69M$175.86M$155.63M$155.97M$141.26M$130.42M$127.07M$129.09M$122.64M
    R&D$97.81M$95.53M$104.40M$99.23M$110.14M$98.26M$93.63M$84.61M$79.60M$81.57M$84.98M$82.53M
    SG&A$104.40M$104.90M$91.72M$69.46M$65.72M$57.37M$62.34M$56.65M$50.82M$45.50M$44.11M$40.11M
    Operating Income$-179,172,000$-183,618,000$-178,366,000$-166,755,000$-111,506,000$-155,631,000$-139,040,000$-140,801,000$-130,172,000$-126,235,000$-127,418,000$-122,265,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$34.83M$33.34M$30.34M$147.57M$24.27M$22.95M$22.59M$22.30M$24.30M$17.32M$17.06M$14.00M
    Income Before Tax$-212,703,000$-217,053,000$-194,501,000$-316,426,000$-147,371,000$-175,077,000$-165,034,000$-177,599,000$-154,871,000$-143,556,000$-158,100,000$-129,422,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-198,762,000$-206,031,000$-183,031,000$-306,178,000$-134,370,000$-161,376,000$-150,020,000$-160,545,000$-143,318,000$-135,643,000$-136,896,000$-129,422,000
    EBITDA$-178,593,000$-182,214,000$-164,380,000$-168,872,000$-124,853,000$-156,005,000$-147,758,000$-163,981,000$-136,665,000$-129,128,000$-139,802,000$-117,308,000
    EBIT$-177,872,000$-183,718,000$-164,166,000$-168,855,000$-123,106,000$-152,131,000$-142,440,000$-155,301,000$-130,572,000$-126,235,000$-141,036,000$-115,426,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CYTK

    News

    William Blair initiates Cytokinetics stock coverage with outperform rating

    William Blair has initiated coverage of Cytokinetics Inc. (NASDAQ: CYTK) with an Outperform rating and a price target of $101 per share...

    Investing.com•10/15/26•Bullish

    Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today

    Cytokinetics (NASDAQ: CYTK) has shown strong market outperformance over the past 15 years, with an average annual return of 15.73%. An initial investment of $1000 in CYTK stock 15 years ago would now be worth $8,804.41...

    Benzinga•10/15/26•Bullish

    Is Cytokinetics (CYTK) Undervalued As New Aficamten Phase 3 Data Supports Expansion?

    Cytokinetics (CYTK) is under renewed focus after presenting new Phase 3 ACACIA-HCM data for aficamten, showing its effect on exercise performance in non-obstructive hypertrophic cardiomyopathy. Despite recent share price...

    Simply Wall Street•10/15/26•Bullish

    Is Cytokinetics (CYTK) Undervalued As New Aficamten Phase 3 Data Supports Expansion?

    Cytokinetics (CYTK) is considered 41% undervalued by Simply Wall St, trading at $63.43 against a fair value of $107.80...

    Simply Wall Street•10/15/26•Bullish

    UBS Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $104

    UBS has reiterated its Buy rating on Cytokinetics (CYTK.US) but has reduced the target price for the company's stock to $104. This adjustment suggests a continued positive outlook on Cytokinetics by UBS...

    Moomoo•10/15/26•Somewhat-Bearish

    CYTK Valuation and Fair Value

    P/E
    -10.3x
    Forward P/E
    117.7x
    P/FCF
    -14.5x
    PEG
    -0.4x
    P/B
    -48.7x
    See GNG's fair value

    CYTK Profitability: Margins, ROIC and FCF

    Gross margin
    88.0%
    Operating margin
    -626.0%
    Net margin
    0.0%
    ROIC
    -56.4%
    ROE
    -572.0%
    FCF margin
    -858.2%
    FCF yield
    -6.9%

    CYTK Competitors

    CompanyTicker
    Protagonist Therapeutics IncPTGX
    Kymera Therapeutics IncKYMR
    Insulet CorporationPODD
    Caris Life Sciences, Inc. Common StockCAI
    Qiagen NVQGEN
    Hinge Health, Inc.HNGE
    10X Genomics IncTXG
    Bruker CorporationBRKR

    Sector: Healthcare

    CYTK Analyst Ratings

    Consensus
    Buy
    Analysts
    22
    Strong Buy
    7
    Buy
    13
    Hold
    2
    Sell
    0
    Strong Sell
    0

    CYTK Bull Case vs Bear Case

    Bull case

    • 90.9% of CYTK's analyst ratings are Buy or Strong Buy.

    Bear case

    • CYTK's quarterly revenue changed -57.1% year over year.

    CYTK Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    1.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.43
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    11 up, 3 down

    Frequently Asked Questions About CYTK

    Does CYTK pay dividends?

    Cytokinetics Inc (CYTK) does not currently pay a regular dividend.

    What is CYTK's market cap?

    Cytokinetics Inc (CYTK) has a market capitalization of $8.82B with a current stock price of $63.92.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In